CD274 and head and neck squamous cell carcinoma: For example, window-of-opportunity studies in HPV− HNSCCs utilizing PD1 or PDL1-targeting immune therapy have shown improved outcomes in intermediate-risk HNSCC patients [9] and in locally advanced resectable HNSCC (KEYNOTE-689).